Guoke Hengtai provides 70 million yuan guarantee for its subsidiary

Radar Finance | Written by Yang Yang | Edited by Li Yihui

On March 9, Guoke Hengtai (Stock Code: 301370) announced that it will provide guarantees for its subsidiaries Guoke Hengsheng (Beijing) Medical Technology Co., Ltd. and Guoke Hengkai (Shanghai) Medical Technology Co., Ltd. Specifically, Guoke Hengsheng applied for a credit line of 50 million yuan from Huaxia Bank, while Guoke Hengkai applied for a 20 million yuan credit line from China Merchants Bank. Both guarantees are jointly guaranteed by the parent company.

This guarantee is within the approved guarantee limit and does not require further board approval. The announcement also disclosed basic information, financial status, and main terms of the guarantee contracts for the guaranteed subsidiaries.

Currently, the total guarantee amount for the company and its controlling subsidiaries is 1,854.7261 million yuan, accounting for 74.88% of the latest audited net assets. The actual guarantee balance is 745.496 million yuan, representing 30.10%. Notably, as of now, the company has no overdue guarantees.

According to Tianyancha, Guoke Hengtai was established on February 7, 2013, with a registered capital of 470.60 million yuan. The legal representative is Liu Bing. The registered address is Room 501C, 5th Floor, Building 6, No. 25 Jinghai 4th Road, Beijing Economic and Technological Development Zone. Its main business includes distribution and direct sales of medical devices, along with providing warehousing, logistics, distribution channel management, information management during circulation, and hospital SPD operation management services.

Currently, the company’s chairman is Liu Bing, the secretary is Wang Xiaobei, with 1,005 employees. The actual controlling shareholder is China Academy of Sciences Holdings Co., Ltd.

The company has stakes in 94 subsidiaries, including Xiamen Guoke Hengtai Medical Technology Co., Ltd., Shaanxi Hengzhi Medical Technology Co., Ltd., Shanghai Hengjing Medical Technology Co., Ltd., Hebei Guoke Henglong Medical Technology Co., Ltd., and Henan Guoke Hengxuan Medical Technology Co., Ltd.

In terms of performance, the company’s revenue for 2022, 2023, and 2024 was 6.36 billion yuan, 7.483 billion yuan, and 7.346 billion yuan, respectively, with year-over-year growth of 8.76%, 17.66%, and -1.82%. Net profit attributable to the parent was 124 million yuan, 154 million yuan, and 131 million yuan, with YoY growth of -18.17%, 23.19%, and -15.09%. During the same period, the company’s asset-liability ratio was 78.65%, 63.75%, and 61.39%.

Regarding risks, Tianyancha data shows the company has 278 internal Tianyan risks, 468 surrounding risks, 4 historical risks, and 910 warning alerts.